Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ADDITIONAL PAID-IN CAPITAL Cumulative Effect, Period of Adoption, Adjustment	ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED DEFICIT	ACCUMULATED DEFICIT Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020			46,821,644
Beginning balance at Dec. 31, 2020	$ 23,968		$ 47	$ 1,103,074		$ (52)	$ (1,079,101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			62,016
Issuance of common stock upon exercise of stock options	26			26
Issuance of common stock for restricted stock awards, net (in shares)			10,162
Issuance of common stock for restricted stock awards, net	(1,127)			(1,127)
Stock-based compensation	8,741			8,741
Other comprehensive income (loss)	(12)					(12)
Net loss	(41,964)						(41,964)
Ending balance (in shares) at Mar. 31, 2021			46,893,822
Ending balance at Mar. 31, 2021	(10,368)		$ 47	1,110,714		(64)	(1,121,065)
Beginning balance (in shares) at Dec. 31, 2020			46,821,644
Beginning balance at Dec. 31, 2020	23,968		$ 47	1,103,074		(52)	(1,079,101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	(7)
Net loss	(120,343)
Ending balance (in shares) at Sep. 30, 2021			47,179,733
Ending balance at Sep. 30, 2021	(72,876)		$ 47	1,126,580		(59)	(1,199,444)
Beginning balance (in shares) at Dec. 31, 2020			46,821,644
Beginning balance at Dec. 31, 2020	23,968		$ 47	1,103,074		(52)	(1,079,101)
Ending balance (in shares) at Dec. 31, 2021			48,444,473
Ending balance at Dec. 31, 2021	$ (17,333)	$ (76,704)	$ 48	1,136,656	$ (124,666)	(126)	(1,153,911)	$ 47,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06
Beginning balance (in shares) at Mar. 31, 2021			46,893,822
Beginning balance at Mar. 31, 2021	$ (10,368)		$ 47	1,110,714		(64)	(1,121,065)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			18,426
Issuance of common stock upon exercise of stock options	91			91
Issuance of common stock for restricted stock awards, net (in shares)			(7,400)
Issuance of common stock for restricted stock awards, net	(13)			(13)
Stock-based compensation	8,363			8,363
Other comprehensive income (loss)	3					3
Net loss	(38,688)						(38,688)
Issuance of common stock upon exercise of stock purchase rights (in shares)			89,555
Issuance of common stock upon exercise of stock purchase rights	998			998
Ending balance (in shares) at Jun. 30, 2021			46,994,403
Ending balance at Jun. 30, 2021	(39,614)		$ 47	1,120,153		(61)	(1,159,753)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			8,897
Issuance of common stock upon exercise of stock options	112			112
Issuance of common stock for restricted stock awards, net (in shares)			176,433
Issuance of common stock for restricted stock awards, net	(502)			(502)
Stock-based compensation	6,817			6,817
Other comprehensive income (loss)	2					2
Net loss	(39,691)						(39,691)
Ending balance (in shares) at Sep. 30, 2021			47,179,733
Ending balance at Sep. 30, 2021	(72,876)		$ 47	1,126,580		(59)	(1,199,444)
Beginning balance (in shares) at Dec. 31, 2021			48,444,473
Beginning balance at Dec. 31, 2021	(17,333)	(76,704)	$ 48	1,136,656	(124,666)	(126)	(1,153,911)	47,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for restricted stock awards, net (in shares)			191,227
Issuance of common stock for restricted stock awards, net	(358)			(358)
Stock-based compensation	4,878			4,878
Other comprehensive income (loss)	(304)					(304)
Net loss	(35,891)						(35,891)
Ending balance (in shares) at Mar. 31, 2022			48,635,700
Ending balance at Mar. 31, 2022	(125,712)		$ 48	1,016,510		(430)	(1,141,840)
Beginning balance (in shares) at Dec. 31, 2021			48,444,473
Beginning balance at Dec. 31, 2021	$ (17,333)	$ (76,704)	$ 48	1,136,656	$ (124,666)	(126)	(1,153,911)	$ 47,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	204,227
Other comprehensive income (loss)	$ (677)
Net loss	(82,088)
Ending balance (in shares) at Sep. 30, 2022			49,390,503
Ending balance at Sep. 30, 2022	(163,982)		$ 49	1,024,809		(803)	(1,188,037)
Beginning balance (in shares) at Mar. 31, 2022			48,635,700
Beginning balance at Mar. 31, 2022	(125,712)		$ 48	1,016,510		(430)	(1,141,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for restricted stock awards, net (in shares)			20,505
Issuance of common stock for restricted stock awards, net	(25)			(25)
Stock-based compensation	4,146			4,146
Other comprehensive income (loss)	(363)					(363)
Net loss	(19,371)						(19,371)
Issuance of common stock upon exercise of stock purchase rights (in shares)			30,043
Issuance of common stock upon exercise of stock purchase rights	191			191
Ending balance (in shares) at Jun. 30, 2022			48,686,248
Ending balance at Jun. 30, 2022	(141,134)		$ 48	1,020,822		(793)	(1,161,211)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)			197,701
Issuance of common stock upon exercise of stock options	679			679
Issuance of common stock for restricted stock awards, net (in shares)			506,554
Issuance of common stock for restricted stock awards, net	(491)		$ 1	(492)
Stock-based compensation	3,800			3,800
Other comprehensive income (loss)	(10)					(10)
Net loss	(26,826)						(26,826)
Ending balance (in shares) at Sep. 30, 2022			49,390,503
Ending balance at Sep. 30, 2022	$ (163,982)		$ 49	$ 1,024,809		$ (803)	$ (1,188,037)

AERIE PHARMACEUTICALS INC 10-Q